All Studies Meta Analysis Recent:

Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19

Kow et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441

Aug 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020

^*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19ivm.org

Review of sample size calculations in ivermectin RCTs, showing that existing RCTs are very underpowered.

Reviews covering ivermectin for COVID-19 include Adegboro, Al-kuraishy, Babalola, Behl, Bray, DiNicolantonio, DiNicolantonio (B), Elkholy, Fordham, Formiga, Heidary, Jagiasi, Jans, Jans (B), Kory, Kory (B), Kory (C), Kory (D), Kow, Lind, Liu, Loo, Low, Santin, Scheim, Scheim (B), Schwartz, Semiz, Turkia, Turkia (B), Turkia (C), Vora, Wang, Wehbe, Yagisawa, Yagisawa (B), Yemeke, Zaidi.

Important missing comments or errors? Let us know.

1. Adegboro et al., A review of the anti-viral effects of ivermectin, African Journal of Clinical and Experimental Microbiology, doi:10.4314/ajcem.v22i3.2.ajol.info, doi.org.

2. Al-kuraishy et al., Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia, Current Drug Targets, doi:10.2174/1389450123666220810102406.eurekaselect.com, doi.org.

3. Babalola et al., The Place of Ivermectin in the Management of Covid-19: State of the Evidence, Medical Research Archives, doi:10.18103/mra.v11i4.3778.esmed.org, doi.org.

4. Behl et al., CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.sciencedirect.com, doi.org.

5. Bray et al., Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res., doi:10.1016/j.antiviral.2020.104805.nih.gov, doi.org.

6. DiNicolantonio et al., Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors, Open Heart, doi:10.1136/openhrt-2021-001655.bmj.com, doi.org.

7. DiNicolantonio (B) et al., Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, doi:10.1136/openhrt-2020-001350.bmj.com, doi.org.

8. Elkholy et al., Ivermectin: A Closer Look at a Potential Remedy, Cureus, doi:10.7759/cureus.10378.cureus.com, doi.org.

9. Fordham et al., The uses and abuses of systematic reviews, OSF Preprints, doi:10.31219/osf.io/mp4f2.osf.io, doi.org.

10. Formiga et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J. Control Release, doi:10.1016/j.jconrel.2020.10.009.nih.gov, doi.org.

11. Heidary et al., Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z.nature.com, doi.org.

12. Jagiasi et al., Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey, The International Journal of Clinical Practice, doi:10.1111/ijcp.14574.wiley.com, doi.org.

13. Jans et al., The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?, Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.10.042.sciencedirect.com, doi.org.

14. Jans (B) et al., Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?, Cells 2020, 9:9, 2100, doi:10.3390/cells9092100.mdpi.com, doi.org.

15. Kory, P., The Global War on Ivermectin, International Covid Summit III, European Parliament, Brussels, covid19criticalcare.com/wp-content/uploads/2023/05/GLOBAL-WAR-ON-IVERMECTIN-PARLIAMENT.pdf.covid19criticalcare.com.

16. Kory (B), P., The Criminal Censorship of Ivermectin's Efficacy By The High-Impact Medical Journals - Part 1, Pierre Kory’s Medical Musings, pierrekory.substack.com/p/the-criminal-censorship-of-ivermectins.substack.com.

17. Kory (C) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.lww.com, doi.org.

18. Kory (D) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369.archive.org, doi.org.

19. Kow et al., Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441.lww.com, doi.org.

20. Lind et al., Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis, Journal of General Internal Medicine, doi:10.1007/s11606-021-06948-6.springer.com, doi.org.

21. Liu et al., Crosstalk between neutrophil extracellular traps and immune regulation: insights into pathobiology and therapeutic implications of transfusion-related acute lung injury, Frontiers in Immunology, doi:10.3389/fimmu.2023.1324021.frontiersin.org, doi.org.

22. Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.springer.com, doi.org.

23. Low et al., Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166294.sciencedirect.com, doi.org.

24. Santin et al., Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections, doi:10.1016/j.nmni.2021.100924.sciencedirect.com, doi.org.

25. Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.mdpi.com, doi.org.

26. Scheim (B) et al., Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms242317039.mdpi.com, doi.org.

27. Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.sciencedirect.com, doi.org.

28. Semiz, S., SIT1 transporter as a potential novel target in treatment of COVID-19, Biomolecular Concepts, doi:10.1515/bmc-2021-0017.degruyter.com, doi.org.

29. Turkia, M., A Continuation of a Timeline of Ivermectin-Related Events in the COVID-19 Pandemic [June 30, 2021], ResearchGate, doi:10.13140/RG.2.2.16973.36326.researchgate.net, doi.org.

30. Turkia (B), M., A timeline of ivermectin-related events in the COVID-19 pandemic, Research Gate, www.researchgate.net/publication/350610718_A_Timeline_of_Ivermectin-Related_Events_in_the_COVID-19_Pandemic_April_3_2021.researchgate.net.

31. Turkia (C), M., FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review, ResearchGate, www.researchgate.net/profile/Mika_Turkia/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review/links/5fab010f4585150781078260/FLCCC-Alliance-MATH-ascorbic-acid-and-I-MASK-ivermectin-protocols-for-COVID-19-A-Brief-Review.pdf.researchgate.net.

32. Vora et al., White paper on Ivermectin as a potential therapy for COVID-19, Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031.sciencedirect.com, doi.org.

33. Wang et al., Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19, medRxiv, doi:10.1101/2021.06.01.21258147.medrxiv.org, doi.org.

34. Wehbe et al., Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities, Front. Immunol., doi:10.3389/fimmu.2021.663586.frontiersin.org, doi.org.

35. Yagisawa et al., Global trends in clinical trials of ivermectin for COVID-19—Part 2, The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.77.1_45.doi.org, doi.org.

36. Yagisawa (B) et al., Global trends in clinical studies of ivermectin in COVID-19, The Japanese Journal of Antibiotics, 74-1, Mar 2021, jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf.wdc-jp.com.

37. Yemeke et al., Impact of the COVID-19 pandemic on the quality of medical products in Zimbabwe: a qualitative study based on key informant interviews with health system stakeholders, BMJ Open, doi:10.1136/bmjopen-2022-068923.bmj.com, doi.org.

38. Zaidi et al., The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review, The Journal of Antibiotics, doi:10.1038/s41429-021-00491-6.nature.com, doi.org.

Kow et al., 6 Aug 2021, peer-reviewed, 2 authors.

This Paper Ivermectin All

{ 'DOI': '10.1097/mjt.0000000000001441', 'ISSN': ['1075-2765'], 'URL': 'http://dx.doi.org/10.1097/MJT.0000000000001441', 'author': [ { 'affiliation': [ { 'name': 'School of Pharmacy, Monash University Malaysia Bandar Sunway, ' 'Selangor, Malaysia'}, { 'name': 'School of Postgraduate Studies, International Medical ' 'University, Kuala Lumpur, Malaysia'}], 'family': 'Kow', 'given': 'Chia Siang', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'School of Applied Sciences, University of Huddersfield, ' 'Huddersfield, United Kingdom'}, { 'name': 'School of Biomedical Sciences and Pharmacy University of ' 'Newcastle, Callaghan, Australia'}], 'family': 'Hasan', 'given': 'Syed S.', 'sequence': 'additional'}], 'container-title': 'American Journal of Therapeutics', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 8, 13]], 'date-time': '2021-08-13T13:55:18Z', 'timestamp': 1628862918000}, 'deposited': { 'date-parts': [[2023, 9, 17]], 'date-time': '2023-09-17T04:19:01Z', 'timestamp': 1694924341000}, 'indexed': {'date-parts': [[2023, 9, 18]], 'date-time': '2023-09-18T04:35:25Z', 'timestamp': 1695011725354}, 'is-referenced-by-count': 4, 'issue': '5', 'issued': {'date-parts': [[2021, 8, 6]]}, 'journal-issue': {'issue': '5', 'published-online': {'date-parts': [[2021]]}}, 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001441', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '276', 'original-title': [], 'page': 'e616-e619', 'prefix': '10.1097', 'published': {'date-parts': [[2021, 8, 6]]}, 'published-online': {'date-parts': [[2021, 9]]}, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'reference': [ { 'DOI': '10.1016/S1473-3099(20)30120-1', 'article-title': 'An interactive web-based dashboard to track COVID-19 in real time', 'author': 'Dong', 'doi-asserted-by': 'crossref', 'first-page': '533', 'journal-title': 'Lancet Infect Dis.', 'key': 'R1-20230917', 'volume': '20', 'year': '2020'}, { 'article-title': 'The use of remdesivir for the management of patients with ' 'moderate-to-severe COVID-19: a systematic review', 'author': 'Thiruchelvam', 'journal-title': 'Expert Rev Anti Infect Ther.', 'key': 'R2-20230917', 'year': '2021'}, { 'DOI': '10.1080/17476348.2021.1925546', 'article-title': 'Does methylprednisolone reduce the mortality risk in hospitalized ' 'COVID-19 patients? A meta-analysis of randomized control trials', 'author': 'Hasan', 'doi-asserted-by': 'crossref', 'journal-title': 'Expert Rev Respir Med.', 'key': 'R3-20230917', 'year': '2021'}, { 'DOI': '10.1007/s43440-021-00245-z', 'article-title': 'The association between the use of ivermectin and mortality in patients ' 'with COVID-19: a meta-analysis', 'author': 'Kow', 'doi-asserted-by': 'crossref', 'journal-title': 'Pharmacol Rep.', 'key': 'R4-20230917', 'year': '2021'}, { 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'Caly', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'journal-title': 'Antivir Res', 'key': 'R5-20230917', 'volume': '178', 'year': '2020'}, { 'DOI': '10.1371/journal.pbio.3001162', 'article-title': 'The methodological quality of 176,620 RCTs published between 1966 and ' '2018 reveals a positive trend but also an urgent need for improvement', 'author': 'Vinkers', 'doi-asserted-by': 'crossref', 'first-page': 'e3001162', 'journal-title': 'PLoS Biol.', 'key': 'R6-20230917', 'volume': '19', 'year': '2021'}, { 'DOI': '10.1016/j.ijid.2020.09.1470', 'article-title': 'Use of hydroxychloroquine and chloroquine in COVID-19: how good is the ' 'quality of RCTs?', 'author': 'Mazhar', 'doi-asserted-by': 'crossref', 'first-page': '107', 'journal-title': 'Int J Infect Dis.', 'key': 'R7-20230917', 'volume': '101', 'year': '2020'}, { 'DOI': '10.1016/j.chest.2020.03.010', 'article-title': 'Sample size estimation in clinical research: from RCTs to observational ' 'studies', 'author': 'Wang', 'doi-asserted-by': 'crossref', 'first-page': 'S12', 'journal-title': 'Chest', 'key': 'R8-20230917', 'volume': '158', 'year': '2020'}, { 'DOI': '10.1097/MJT.0000000000001402', 'article-title': 'Ivermectin for prevention and treatment of COVID-19 infection: a ' 'systematic review, meta-analysis, and trial sequential analysis to ' 'inform clinical guidelines', 'author': 'Bryant', 'doi-asserted-by': 'crossref', 'first-page': 'e434', 'journal-title': 'Am J Ther.', 'key': 'R9-20230917', 'volume': '28', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2021436', 'article-title': 'Dexamethasone in hospitalized patients with covid-19', 'author': 'Horby', 'doi-asserted-by': 'crossref', 'first-page': '693', 'journal-title': 'N Engl J Med.', 'key': 'R10-20230917', 'volume': '384', 'year': '2021'}, { 'DOI': '10.1186/s12874-020-01101-z', 'article-title': 'Statistical design of Phase II/III clinical trials for testing ' 'therapeutic interventions in COVID-19 patients', 'author': 'Rai', 'doi-asserted-by': 'crossref', 'first-page': '220', 'journal-title': 'BMC Med Res Methodol', 'key': 'R11-20230917', 'volume': '20', 'year': '2020'}, { 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'author': 'López-Medina', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'journal-title': 'JAMA', 'key': 'R12-20230917', 'volume': '325', 'year': '2021'}, { 'article-title': 'Ivermectin as a potential treatment for mild to moderate COVID-19—a ' 'double blind randomized placebo-controlled trial', 'author': 'Ravikirti', 'first-page': '10', 'journal-title': 'medRxiv', 'key': 'R14-20230917', 'volume': '2021', 'year': '2021'}, { 'DOI': '10.1080/20477724.2021.1890887', 'article-title': 'Phase 2 randomized study on chloroquine, hydroxychloroquine or ' 'ivermectin in hospitalized patients with severe manifestations of ' 'SARS-CoV-2 infection', 'author': 'Galan', 'doi-asserted-by': 'crossref', 'first-page': '235', 'journal-title': 'Pathog Glob Health', 'key': 'R15-20230917', 'volume': '115', 'year': '2021'}, { 'article-title': 'Efficacy and safety of ivermectin and hydroxychloroquine in patients ' 'with severe COVID-19. A randomized controlled trial', 'author': 'Gonzalez', 'journal-title': 'Preprint Medrxiv.', 'key': 'R16-20230917', 'year': '2021'}, { 'article-title': 'Controlled randomized clinical trial on using ivermectin with ' 'doxycycline for treating COVID-19 patients in Baghdad, Iraq', 'author': 'Hashim', 'journal-title': 'Preprint Medrxiv.', 'key': 'R17-20230917', 'year': '2020'}, { 'DOI': '10.1186/s12879-021-06104-9', 'article-title': 'Evaluation of the effectiveness and safety of adding ivermectin to ' 'treatment in severe COVID-19 patients', 'author': 'Okumus', 'doi-asserted-by': 'crossref', 'first-page': '411', 'journal-title': 'BMC Infect Dis', 'key': 'R18-20230917', 'volume': '21', 'year': '2021'}, { 'article-title': 'Ivermectin as an adjunct treatment for hospitalized adult COVID-19 ' 'patients: a randomized multi-center clinical trial', 'author': 'Niaee', 'journal-title': 'Preprint Res Square', 'key': 'R19-20230917', 'year': '2020'}, { 'article-title': 'Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'author': 'Horby', 'journal-title': 'Preprint Medrxiv.', 'key': 'R20-20230917', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(21)00149-5', 'article-title': 'Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): ' 'a randomised, controlled, open-label, platform trial', 'doi-asserted-by': 'crossref', 'first-page': '605', 'journal-title': 'Lancet', 'key': 'R21-20230917', 'volume': '397', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of hydroxychloroquine in hospitalized patients with covid-19', 'author': 'Horby', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'journal-title': 'N Engl J Med.', 'key': 'R22-20230917', 'volume': '383', 'year': '2020'}, { 'article-title': 'Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'author': 'Horby', 'first-page': '55', 'journal-title': 'Preprint Medrxiv.', 'key': 'R23-20230917', 'volume': '2021', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(21)00897-7', 'article-title': 'Convalescent plasma in patients admitted to hospital with COVID-19 ' '(RECOVERY): a randomised controlled, open-label, platform trial', 'doi-asserted-by': 'crossref', 'first-page': '2049', 'journal-title': 'Lancet', 'key': 'R24-20230917', 'volume': '397', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(20)32013-4', 'article-title': 'Lopinavir-ritonavir in patients admitted to hospital with COVID-19 ' '(RECOVERY): a randomised, controlled, open-label, platform trial', 'doi-asserted-by': 'crossref', 'first-page': '1345', 'journal-title': 'Lancet', 'key': 'R25-20230917', 'volume': '396', 'year': '2020'}], 'reference-count': 24, 'references-count': 24, 'relation': {}, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001441'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving ' 'Ivermectin for the treatment of COVID-19', 'type': 'journal-article', 'volume': '28'}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0